Apyx Medical Corporation (APYX) Stock Price, News & Analysis

Apyx Medical Corporation (NASDAQ: APYX) is described as a surgical aesthetics and advanced energy technology company focused on medical devices. According to company disclosures and recent press releases, it develops, manufactures, and markets products based on its Helium Plasma Platform Technology, which are used in both the cosmetic surgery market and the hospital surgical market.

The company’s products are marketed and sold under several brands. In the cosmetic surgery market, Apyx Medical offers Renuvion and the AYON Body Contouring System™ (AYON). In the hospital surgical market, it offers J-Plasma®. Company materials state that Renuvion and J-Plasma provide surgeons with a unique ability to deliver controlled heat to tissue to achieve desired results, and that the effectiveness of these technologies is supported by more than 90 clinical documents or publications.

Apyx Medical also reports operating through an Advanced Energy segment and an Original Equipment Manufacturing (OEM) segment. The Advanced Energy segment includes its Helium Plasma Platform Technology products, while the OEM business leverages the company’s experience in unique waveforms through agreements with other medical device manufacturers. Company information notes that the Advanced Energy segment has historically generated the majority of its revenue.

Core technologies and product platforms

The company’s Helium Plasma Platform Technology underpins multiple branded systems. Renuvion is described as a cosmetic technology that offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to tissue. J-Plasma is presented as a system that allows surgeons to operate with a high level of precision. Apyx Medical states that these technologies are used in cosmetic surgery settings and hospital operating rooms, respectively.

The AYON Body Contouring System™ is highlighted in recent company communications as an FDA-cleared, surgeon-designed body contouring platform. Apyx Medical describes AYON as an all-in-one system that integrates fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities. In some disclosures, the company notes that AYON incorporates Renuvion technology and is intended for the aesthetic surgical suite. Company statements also reference features such as procedural presets by body part and an advanced gas system when describing the related Apyx One console.

Business segments and OEM activities

In addition to its branded surgical aesthetics products, Apyx Medical reports an OEM revenue stream. The company indicates that it leverages its “deep expertise and decades of experience in unique waveforms” to supply other medical device manufacturers under OEM agreements. Public filings and press releases refer to OEM segment revenue separately from Surgical Aesthetics revenue, reflecting the company’s internal reporting structure.

Company disclosures also reference a 10-year generator manufacturing and supply agreement with another medical device company within the OEM segment, illustrating how Apyx Medical’s technology and manufacturing capabilities are used in third-party products.

Geographic and market presence

Apyx Medical is identified in SEC filings as a Delaware corporation with executive offices in Clearwater, Florida. Press releases describe the company as listed on the Nasdaq Capital Market under the symbol APYX. The company reports revenue from both domestic and international markets and has announced regulatory approvals and commercial launches in specific countries, including the approval and commercial launch of the Apyx One console and single-use handpieces for cosmetic surgical procedures in South Korea following clearance by the Ministry of Food and Drug Safety.

In its communications, Apyx Medical characterizes itself as a participant in the surgical aesthetics market and notes activity in cosmetic surgery markets in the U.S., Europe, and South Korea, as well as the hospital surgical market for J-Plasma.

Corporate and capital markets activity

The company’s SEC filings and press releases show ongoing capital markets and corporate governance activity. In an 8-K dated November 19, 2025, Apyx Medical reported entering into an underwriting agreement with Lucid Capital Markets, LLC for a public offering of its common stock under an effective shelf registration statement on Form S-3. The company stated that it expected to use net proceeds for working capital and general corporate purposes, including expanding sales and marketing, capital expenditures, possible acquisitions of complementary businesses, products, or technologies, and repayment of indebtedness it may incur.

In another 8-K filed on December 12, 2025, the company reported that stockholders had approved, and it had filed, a Certificate of Amendment to its Certificate of Incorporation to remove Article EIGHTH and replace it with “intentionally omitted.” This followed approval at the 2025 annual meeting of stockholders, as described in the company’s definitive proxy statement on Schedule 14A.

Financial reporting and guidance

Apyx Medical regularly reports its financial results and operating metrics via press releases that are furnished on Form 8-K. For example, on November 6, 2025, the company issued a press release reporting results for the quarter ended September 30, 2025, including revenue by segment and geography. The same release discussed the commercial launch of the AYON Body Contouring System in the U.S. and referenced guidance for full-year 2025 revenue, with separate expectations for Surgical Aesthetics and OEM revenue.

On January 12, 2026, the company released preliminary, unaudited revenue results for the fourth quarter and full year 2025. In that release, Apyx Medical reported expected ranges for total revenue, Surgical Aesthetics revenue, and OEM revenue, and noted year-over-year percentage changes for each category. The company stated that actual results remained subject to completion of year-end closing and audit procedures.

Regulatory and clinical context

Company communications emphasize that its Helium Plasma Platform Technology products, including Renuvion and J-Plasma, are supported by more than 90 clinical documents or publications. Apyx Medical also notes that AYON is an FDA-cleared system and has referenced submissions of 510(k) premarket notifications to the U.S. Food and Drug Administration for label expansions, such as for power liposuction.

In international markets, the company has highlighted regulatory approvals such as the Ministry of Food and Drug Safety clearance in South Korea for the Apyx One console and single-use handpieces used in cosmetic surgical procedures. These approvals are presented as enabling commercial launches in those markets.

Stock information and governance

Apyx Medical’s common stock is registered under the Exchange Act and trades on Nasdaq under the ticker APYX. The company’s definitive proxy statement for the 2025 annual meeting describes matters submitted to stockholders, including the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation and its frequency, and approval of an amendment to the Certificate of Incorporation.

SEC filings also reference inducement equity awards under Nasdaq Listing Rule 5635(c)(4), such as a nonstatutory stock option grant to a senior sales executive, illustrating the company’s use of equity-based compensation.

How Apyx Medical is categorized

Based on the provided industry classification, Apyx Medical is associated with Surgical and Medical Instrument Manufacturing within the broader Manufacturing sector. Its own descriptions emphasize surgical aesthetics and advanced energy medical devices, with operations organized into Advanced Energy and OEM segments and products used in cosmetic surgery and hospital surgical settings.